Abstract
A pharmaceutical composition for inhibiting NFKBIZ gene expression, and use thereof, are provided. A double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression is designed. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, use of a pharmaceutical composition formed by the conjugation of the designed nucleic acid molecules and targeting ligands is verified in ocular disease treatment.
Full Text
What is claimed is:
A pharmaceutical composition for inhibiting NFKBIZ gene expression, and use thereof, are provided. A double-stranded nucleic acid molecule capable of targeting and regulating NFKBIZ gene expression is designed. By means of verifying the gene regulation efficiency of nucleic acid molecules, multiple nucleic acid molecules capable of inhibiting NFKBIZ gene expression are obtained from screening, and efficient inhibition of IκB-ζ protein expression is achieved at the protein level. In addition, use of a pharmaceutical composition formed by the conjugation of the designed nucleic acid molecules and targeting ligands is verified in ocular disease treatment.
Timeline
Filed
05/08/2026Published
08/20/2026Granted
Not AvailableIPC Codes(3)
C12N 15/113:Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 27/02:Ophthalmic agents
C12N 15/115:Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith